The depot compounds moditen (fluphenazine) and IMAP (fluspirilene) in clinical practice.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014987:Xerostomia / Q000139:chemically induced
D003692:Delayed-Action Preparations; D005464:Fluorobenzenes; D010880:Piperidines; D013141:Spiro Compounds; D014149:Tranquilizing Agents; D005476:Fluphenazine